ýҕl

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • ýҕl Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Community Health Workers
  • Rural Health Payout
  • Measles Outbreaks
  • Doctors’ Liability Premiums
  • Florida’s KidCare

TRENDING TOPICS:

  • Community Health Workers
  • Rural Health Payout
  • Measles Outbreaks
  • Doctors' Liability Premiums
  • Florida’s KidCare

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Tuesday, Mar 31 2020

Full Issue

Meet The Controversial Doctor Who Touts The Use Of Malaria Drugs To Fight Coronavirus

Didier Raoult, the head of a university hospital institute in Marseille, France has been a leading voice in the fight to use a malaria drug to treat COVID-19. But the self-described “maverick” has a storied history of controversial remarks.

Sitting behind his desk in a hospital in the southern French city of Marseille, Didier Raoult has convinced thousands, including the U.S. president, that a common antimalarial drug can save people infected by Covid-19. In a few short weeks, the controversial microbiologist has become France’s best-known doctor after announcing the coronavirus “endgame” on Youtube. (Braun, 3/30)

President Donald Trump made another series of inaccurate and misleading statements during his coronavirus press briefing Monday afternoon from the White House Rose Garden. Trump inaccurately characterized previous statements he has made downplaying the severity of the crisis. He again talked up medications that have not been clinically proven safe or effective for use against the coronavirus. Immediately after boasting about having superior knowledge of South Korea, he misstated the population of Seoul. And in touting progress on coronavirus testing, he omitted important context. (Dale and Cohen, 3/30)

Meanwhile, in other treatment news —

In a new frontier to fight COVID-19, Bay Area researchers are racing to develop new blood tests that can not only help diagnose the disease, but could help determine whether people become immune after catching it and lay the groundwork for a vaccine. Scientists at UCSF and the San Francisco Vitalant Research Institute are among several across the country developing tests. UCSF hopes to start using its test as early as this week, although it won’t be widely available to the public. (Moench, 3/30)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Tuesday, April 28
  • Monday, April 27
  • Friday, April 24
  • Thursday, April 23
  • Wednesday, April 22
  • Tuesday, April 21
More Morning Briefings
RSS Feeds
  • ýҕl
  • Special Reports
  • Morning Briefing
  • About Us
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF